JOCELYN WALKER: Open Payments
NPI 1720657869 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$808 in 19 payments from 10 companies in 2025. Trend: 2023 $3,367 · 2024 $4,110 · 2025 $808
Food & beverage: $728Education: $80
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 6 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $184 |
| AstraZeneca Pharmaceuticals LP | 2 | $130 |
| Merck Sharp & Dohme LLC | 2 | $69 |
| Exelixis Inc. | 1 | $43 |
| Janssen Biotech, Inc. | 1 | $33 |
| GlaxoSmithKline, LLC. | 1 | $32 |
| Syndax Pharmaceuticals, Inc. | 1 | $31 |
| Incyte Corporation | 1 | $28 |
| Celgene Corporation | 1 | $21 |
Products named: LIVTENCITY, CALQUENCE, Cresemba, PREVYMIS, Xospata, DARZALEX, OJJAARA, JAKAFI.
Industry payments across TX — which companies pay providers there.
